Homeopathy is one of the most enduring forms of snake oil available to consumers; it has been duping people since 1814. But the United States government only recently decided to clamp down on these bogus treatments, with a new policy from the Federal Trade Commission.
The FTC’s policy statement explains that the agency will now ask that the makers of homeopathic drugs present reliable scientific evidence for their health claims if they want to sell them to consumers on the US market.
Mustering that evidence is likely to be difficult given that homeopathy is a pseudoscience.
The main idea behind homeopathy is that an animal or plant extract that causes symptoms similar to the ones a person is suffering from can cure the symptoms. An example: Because onions make eyes tear and noses run, diluted onion extract is thought to cure cold and hay fever. So homeopathic remedies on the market are just extremely diluted versions of plant or animal extracts believed to bring relief to symptoms.
The trouble is that whenever researchers have looked at the homeopathic treatments, they find they do not actually contain traceable amounts of the original plant or animal material they were supposedly diluting.
Lumosity to Pay $2 Million to Settle FTC Deceptive Advertising Charges for Its “Brain Training” Program
The creators and marketers of the Lumosity “brain training” program have agreed to settle Federal Trade Commission charges alleging that they deceived consumers with unfounded claims that Lumosity games can help users perform better at work and in school, and reduce or delay cognitive impairment associated with age and other serious health conditions.
As part of the settlement, Lumos Labs, the company behind Lumosity, will pay $2 million in redress and will notify subscribers of the FTC action and provide them with an easy way to cancel their auto-renewal to avoid future billing.
“Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” said Jessica Rich, Director of the FTC’s Bureau of Consumer Protection. “But Lumosity simply did not have the science to back up its ads.”
According to the FTC’s complaint, the Lumosity program consists of 40 games purportedly designed to target and train specific areas of the brain. The company advertised that training on these games for 10 to 15 minutes three or four times a week could help users achieve their “full potential in every aspect of life.” The company sold both online and mobile app subscriptions, with options ranging from monthly ($14.95) to lifetime ($299.95) memberships.